Last Updated: Monday, April 01, 2013, 18:19
Swiss pharma major Novartis Monday said it will not invest on research and development in India and move R&D to favourable destinations following the Supreme Court order rejecting its patent plea on cancer drug Glivec.
Last Updated: Monday, April 01, 2013, 15:09
Novartis, however, said: "This ruling is a setback for patients that will hinder medical progress for diseases without effective treatment options".
Last Updated: Monday, April 01, 2013, 09:27
Glivec, used in treating chronic myeloid leukemia and some other cancers, costs a patient about Rs 1.2 lakh/month, much higher than Rs 8,000 which is the price of the generic drug.
more videos >>